June 3, 2016
Source: Press Release, Prague/Boston
SOTIO, a biotechnology company owned by the PPF Group, presents its clinical development program of DCVAC medicinal products at the 2016 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. DCVAC is an active cellular immunotherapy treatment for patients with cancer. SOTIO attends ASCO 2016 (June 3 to June 7, 2016) with its own exhibition booth and presents its 10 running clinical trials to expert community.
SOTIO is developing new therapies, focusing on the treatment of cancer and autoimmune diseases. The company’s current focus is predominantly on development of its Active Cellular Immunotherapy (ACI) treatment for prostate cancer patients (DCVAC/PCa), patients with ovarian cancer (DCVAC/OvCa), and patients with lung cancer (DCVAC/LuCa). In addition, SOTIO’s in-house research and clinical development teams are investigating potential uses in patients with other indications.
With around 30,000 attendees, the ASCO annual meeting is one of the largest and most prestigious educational and scientific events in the oncology community. The five-day event provides a venue for physicians and scientists to present research results to a global audience of oncology professionals. Clinical trial results and updates presented at ASCO's annual meeting represent the extent of progress globally made each year in the fight against cancer. SOTIO will have an exhibition booth at ASCO for those seeking further information (Hall A, booth number 22105).
About DCVAC clinical trials:
In 2014, SOTIO launched VIABLE, the global Phase III clinical trial of DCVAC/PCa, an active cellular immunotherapy treatment for prostate cancer patients. The trial is recruiting patients from 20 European countries and in the US. Besides the VIABLE study, SOTIO is currently sponsoring five Phase II clinical trials in prostate cancer patients and three Phase II clinical trials in patients with ovarian cancer (DCVAC/OvCa treatment). Clinical testing of DCVAC/LuCa treatment in patients with lung cancer has been launched at the end of 2014.
DCVAC is an active cellular immunotherapy treatment which is produced individually for each patient using the patient’s own dendritic cells (that are part of the immune system), to induce an immune reaction against tumor antigens.